

BME - GROWTH

Palacio de la Bolsa
Plaza de la Lealtad, 1
28014 Madrid

Alicante, 15th of March 2024

COMMUNICATION- PRIVILEGED INFORMATION- FACEPHI BIOMETRIA, S.A.

Dear Sirs,

Under the provisions of article 17 of the Regulation (EU) No. 596/2014 on market abuse, and article 228 of the Law 6/2023 17th March, Spanish Securities Market and Investment Services, and related provisions, as well as in the Circular 3/2020 of BME Growth, we inform you about the following information related to the company FACEPHI BIOMETRIA, S.A. (hereinafter "FacePhi" or "the Company", interchangeably).

FACEPHI BIOMETRÍA, S.A. informed, last 25th March of the signing of a binding Memorandum of Agreement with Hancom Inc. As stated in that communication, and within the term agreed by both parties, Facephi and Hancom have signed, on 14 May 2024, the following agreements:

- Investment by HANCOM of an amount of FIVE MILLION EUROS (5,000,000 €) through a capitalizable loan. That loan will bear an annual interest rate of 0,2% and will be capitalised through a capital increase by offsetting credits, having agreed a conversion price per share of 2.95 euros (0,04 euros as nominal value and 2,91 euros as premium)
- Exclusive Distribution Agreement: HANCOM will act as exclusive distributor in APAC (Asia-Pacific) territory of Facephi's products, solutions and technology. The licensing model will be based on a revenue share system. The agreement will have a duration of three years, renewable by both parties.

In compliance with Circular 3/2020 of the segment BME Growth of BME MTF Equity, it is expressly stated that the information hereby communicated has been produced under the sole responsibility of the company and its administrators.

We remain at your disposal for any clarification you might deem necessary.

Sincerely,

Javier Mira Miró
Chairman of the Board of Directors